| 1. |
- van Bragt, JJMH, et al.
(författare)
-
Characteristics and treatment regimens across ERS SHARP severe asthma registries
- 2020
-
Ingår i: The European respiratory journal. - : European Respiratory Society (ERS). - 1399-3003 .- 0903-1936. ; 55:1
-
Tidskriftsartikel (refereegranskat)abstract
- Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m−2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day−1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day−1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.
|
|
| 2. |
- Billot, N., et al.
(författare)
-
In-situ observations of resident space objects with the CHEOPS space telescope
- 2024
-
Ingår i: Journal of Space Safety Engineering. - 2468-8975 .- 2468-8967. ; In Press
-
Tidskriftsartikel (refereegranskat)abstract
- The CHaracterising ExOPlanet Satellite (CHEOPS) is a partnership between the European Space Agency and Switzerland with important contributions by 10 additional ESA member States. It is the first S-class mission in the ESA Science Programme. CHEOPS has been flying on a Sun-synchronous low Earth orbit since December 2019, collecting millions of short-exposure images in the visible domain to study exoplanet properties. A small yet increasing fraction of CHEOPS images show linear trails caused by resident space objects crossing the instrument field of view. CHEOPS’ orbit is indeed particularly favourable to serendipitously detect objects in its vicinity as the spacecraft rarely enters the Earth's shadow, sits at an altitude of 700 km, and observes with moderate phase angles relative to the Sun. This observing configuration is quite powerful, and it is complementary to optical observations from the ground. To characterize the population of satellites and orbital debris observed by CHEOPS, all and every science images acquired over the past 3 years have been scanned with a Hough transform algorithm to identify the characteristic linear features that these objects cause on the images. Thousands of trails have been detected. This statistically significant sample shows interesting trends and features such as an increased occurrence rate over the past years as well as the fingerprint of the Starlink constellation. The cross-matching of individual trails with catalogued objects is underway as we aim to measure their distance at the time of observation and deduce the apparent magnitude of the detected objects. As space agencies and private companies are developing new space-based surveillance and tracking activities to catalogue and characterize the distribution of small debris, the CHEOPS experience is timely and relevant. With the first CHEOPS mission extension currently running until the end of 2026, and a possible second extension until the end of 2029, the longer time coverage will make our dataset even more valuable to the community, especially for characterizing objects with recurrent crossings.
|
|
| 3. |
- Hellmich, Bernhard, et al.
(författare)
-
EULAR recommendations for the management of ANCA-associated vasculitis : 2022 update
- 2024
-
Ingår i: Annals of the Rheumatic Diseases. - : BMJ. - 0003-4967 .- 1468-2060. ; 83:1, s. 30-47
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials have been published that have the potential to change clinical care and support the need for an update. Methods: Using EULAR standardised operating procedures, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 16 countries. We modified existing recommendations and created new recommendations. Results: Four overarching principles and 17 recommendations were formulated. We recommend biopsies and ANCA testing to assist in establishing a diagnosis of AAV. For remission induction in life-threatening or organ-threatening AAV, we recommend a combination of high-dose glucocorticoids (GCs) in combination with either rituximab or cyclophosphamide. We recommend tapering of the GC dose to a target of 5 mg prednisolone equivalent/day within 4-5 months. Avacopan may be considered as part of a strategy to reduce exposure to GC in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Plasma exchange may be considered in patients with rapidly progressive glomerulonephritis. For remission maintenance of GPA/MPA, we recommend rituximab. In patients with relapsing or refractory eosinophilic GPA, we recommend the use of mepolizumab. Azathioprine and methotrexate are alternatives to biologics for remission maintenance in AAV. Conclusions: In the light of recent advancements, these recommendations provide updated guidance on AAV management. As substantial data gaps still exist, informed decision-making between physicians and patients remains of key relevance.
|
|
